The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy

被引：61

作者：

Claus, Christina ^{[1
,2
]}

Ferrara-Koller, Claudia ^{[1
]}

Klein, Christian ^{[1
]}

机构：

[1] Roche Pharm Res & Early Dev pRED, Roche Innovat Ctr Zurich, Schlieren, Switzerland

[2] Roche Pharm Res & Early Dev pRED, Roche Innovat Ctr Zurich, Wagistr 10, CH-8952 Schlieren, Switzerland

来源：

MABS | 2023年 / 15卷 / 01期

关键词：

CD137; 4-1BB; TNFRSF9; cancer immunotherapy; costimulatory agonist; 4-1BB agonists; bispecific antibodies; PD-L1/4-1BB BISPECIFIC ANTIBODY; TYPE-1 DIABETES DEVELOPMENT; 1ST-IN-HUMAN PHASE-I; T-CELL-ACTIVATION; DOSE-ESCALATION; PRECLINICAL CHARACTERIZATION; CHECKPOINT INHIBITION; MONOCLONAL-ANTIBODIES; ANTITUMOR EFFICACY; CO-STIMULATION;

D O I：

10.1080/19420862.2023.2167189

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

The clinical development of 4-1BB agonists for cancer immunotherapy has raised substantial interest during the past decade. The first generation of 4-1BB agonistic antibodies entering the clinic, urelumab (BMS-663513) and utomilumab (PF-05082566), failed due to (liver) toxicity or lack of efficacy, respectively. The two antibodies display differences in the affinity and the 4-1BB receptor epitope recognition, as well as the isotype, which determines the Fc-gamma-receptor (Fc gamma R) crosslinking activity. Based on this experience a very diverse landscape of second-generation 4-1BB agonists addressing the liabilities of first-generation agonists has recently been developed, with many entering clinical Phase 1 and 2 studies. This review provides an overview focusing on differences and their scientific rationale, as well as challenges foreseen during the clinical development of these molecules.

引用

页数：22

共 150 条

[1] CAR-T Cell Therapies: An Overview of Clinical Studies Supporting Their Approved Use against Acute Lymphoblastic Leukemia and Large B-Cell Lymphomas [J].

Ahmad, Aamir ;

Uddin, Shahab ;

Steinhoff, Martin .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (11) :1-9

[2] Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not? [J].

Albandar, Heidar J. ;

Fuqua, Jacob ;

Albandar, Jasim M. ;

Safi, Salahuddin ;

Merrill, Samuel A. ;

Ma, Patrick C. .

CANCERS, 2021, 13 (05) :1-15

[3] Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma [J].

Barsoumian, Hampartsoum B. ;

Ramapriyan, Rishab ;

Younes, Ahmed, I ;

Caetano, Mauricio S. ;

Menon, Hari ;

Comeaux, Nathan, I ;

Cushman, Taylor R. ;

Schoenhals, Jonathan E. ;

Cadena, Alexandra P. ;

Reilly, Timothy P. ;

Chen, Dawei ;

Masrorpour, Fatemeh ;

Li, Ailin ;

Hong, David S. ;

Diab, Adi ;

Nguyen, Quynh-Nhu ;

Glitza, Isabella ;

Ferrarotto, Renata ;

Chun, Stephen G. ;

Cortez, Maria Angelica ;

Welsh, James .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)

[4] Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway [J].

Bartkowiak, Todd ;

Jaiswal, Ashvin R. ;

Ager, Casey R. ;

Chin, Renee ;

Chen, Chao-Hsien ;

Budhani, Pratha ;

Ai, Midan ;

Reilley, Matthew J. ;

Sebastian, Manu M. ;

Hong, David S. ;

Curran, Michael A. .

CLINICAL CANCER RESEARCH, 2018, 24 (05) :1138-1151

[5] 4-1 BB agonists: multi-potent potentiators of tumor immunity [J].

Bartkowiak, Todd ;

Curran, Michael A. .

FRONTIERS IN ONCOLOGY, 2015, 5

[6] 4-1BB Aptamer-Based Immunomodulation Enhances the Therapeutic Index of Radiation Therapy in Murine Tumor Models [J].

Benaduce, Ana Paula ;

Brenneman, Randall ;

Schrand, Brett ;

Pollack, Alan ;

Gilboa, Eli ;

Ishkanian, Adrian .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02) :458-461

[7] Mechanistic Quantitative Pharmacology Strategies for the Early Clinical Development of Bispecific Antibodies in Oncology [J].

Betts, Alison ;

van der Graaf, Piet H. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (03) :528-541

[8] Crystal structure of the m4-1BB/4-1BBL complex reveals an unusual dimeric ligand that undergoes structural changes upon 4-1BB receptor binding [J].

Bitra, Aruna ;

Doukov, Tzanko ;

Destito, Giuseppe ;

Croft, Michael ;

Zajonc, Dirk M. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2019, 294 (06) :1831-1845

[9] Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade [J].

Blackburn, Shawn D. ;

Shin, Haina ;

Freeman, Gordon J. ;

Wherry, E. John .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (39) :15016-15021

[10] Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function [J].

Buchan, Sarah L. ;

Dou, Lang ;

Remer, Marcus ;

Booth, Steven G. ;

Dunn, Stuart N. ;

Lai, Chester ;

Semmrich, Monika ;

Teige, Ingrid ;

Martensson, Linda ;

Penfold, Christine A. ;

Chan, H. T. Claude ;

Willoughby, Jane E. ;

Mockridge, C. Ian ;

Dahal, Lekh N. ;

Cleary, Kirstie L. S. ;

James, Sonya ;

Rogel, Anne ;

Kannisto, Paivi ;

Jernetz, Mats ;

Williams, Emily L. ;

Healy, Eugene ;

Verbeek, J. Sjef ;

Johnson, Peter W. M. ;

Frendeus, Bjorn ;

Cragg, Mark S. ;

Glennie, Martin J. ;

Gray, Juliet C. ;

Al-Shamkhani, Aymen ;

Beers, Stephen A. .

IMMUNITY, 2018, 49 (05) :958-+

← 1 2 3 4 5 6 7 8 9 10 →